Tetiana Maksymets

Tetiana Maksymets

Auto-generated profile, based on publicly available information

Tetiana Maksymets

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2018
Verified
Journal Article
Closed access
TMTetiana Maksymets
Tetiana Maksymets
NKNatalia Karpyshyn
Natalia Karpyshyn
TGTaras Gutor
Taras Gutor
HSHelen Sklyarova
Helen Sklyarova
ESEugen Sklyarov
Eugen Sklyarov

30 September 2023 in Medical Science of Ukraine (MSU)
Verified
Journal Article
Open access
PDF file
TMT.A Maksymets
T.A Maksymets
HSH.E. Sklyarova
H.E. Sklyarova
Background. Hypolipidemic and hypotensive therapy enables to improve prognosis and decrease the risk of cardiovascular pathologies, however, an intensive regimen of prescribing statins for patients with arterial hypertension (AH) combined with obesity can promote development of hyperinsulinemia and insulin resistance (IR), which are predictors of type 2 diabetes mellitus development. Aim: To investigate the relationship between insulin resistance, adipokines, lipids and low-grade inflammation in patients with cardiovascular disease treated by statins. Materials and methods: 81 patients with overweight and/or obesity and AH or combination of AH and CAD were involved. Patients’ age ranged from 35 to 79 years, among them there were 51 males and 30 females. ACE inhibitors and ARBs, diuretics were used for treatment of AH; atorvastatin was prescribed orally in the dose 20 mg or 40 mg per day permanently as hypolipidemic therapy. Lipid spectrum, biochemical indices and glycated hemoglobin were determined according to common techniques on an analyzer “BioSystems” (Spain) using original kits of reagents. Concentration of insulin and hsCRP were determined on immunochemoluminescent analyzer “Immulite 2000” (Siemens, Germany). Insulin resistance index was calculated by the formula: НОМA-IR=fasting insulin (mcIU/ml)*fasting glucose(mmol/L)/22.5 In НОМA-IR value > 2.77, patients were considered insulin resistant. Leptin was measured using an ELISA kit DRG (USA). Adiponectin was quantified using the ELISA kit Mediagnost (Germany). Results. It has been revealed in our investigation that body mass index, the level of systolic blood pressure, triglycerides, highly sensitive C-reactive protein and leptin were reliably higher in patients with IR, whereas adiponectin level was lower. These associations are confirmed by the results of studying correlations between IR index, adipokines, anthropometric and biochemical parameters. Thus, thorough evaluation of carbohydrate and adipokine profile in patients with cardiovascular pathology combined with obesity, who are subjected to hypolipidemic therapy, is an important factor in preventing type 2 diabetes mellitus. Conclusion. Assessment of the risk of statin-induced diabetes mellitus is important for determining intensity of statin therapy, namely, presence of insulin resistance, levels of hsCRP and adipokines should be considered at the beginning and during treatment. Актуальність. Гіполіпідемічна та гіпотензивна терапія дозволяє покращити прогноз та знизити ризик розвитку серцево-судинної патології, однак інтенсивний режим призначення статинів хворим на артеріальну гіпертензію (АГ) у поєднанні з ожирінням може сприяти розвитку гіперінсулінемії та інсулінорезистентності (ІР), що є предикторами виникнення цукрового діабету 2 типу. Ціль: дослідити зв’язок між інсулінорезистентністю, адипокінами, ліпідами та низькорівневим запаленням у пацієнтів із серцево-судинними захворюваннями, які лікуються статинами. Матеріали і методи. Залучено 81 пацієнта з надлишковою масою тіла та/або ожирінням та АГ або поєднанням АГ та ІХС. Вік хворих від 35 до 79 років, серед них 51 чоловік і 30 жінок. Для лікування АГ використовували інгібітори АПФ та БРА, діуретики; аторвастатин призначали перорально в дозі 20 мг або 40 мг на добу постійно. Ліпідний спектр, біохімічні показники та глікований гемоглобін визначали за загальноприйнятими методиками на аналізаторі “BioSystems” (Іспанія) з використанням оригінальних наборів реактивів. Концентрацію інсуліну та високочутливого С-реактивного протеїну (вчСРП) визначали на імунохемолюмінесцентному аналізаторі «Immulite 2000» (Siemens, Німеччина). Індекс інсулінорезистентності розраховували за формулою: НОМА-IR =інсулін натще (мкМО/мл)*глюкоза натще (ммоль/л)/22,5 При значенні НОМА-IR > 2,77 пацієнти вважалися інсулінорезистентними. Лептин вимірювали за допомогою набору ELISA DRG (США). Кількісне визначення адипонектину проводили за допомогою набору ELISA Mediagnost (Німеччина). Результати. У нашому дослідженні було виявлено, що індекс маси тіла, рівень систолічного артеріального тиску, тригліцеридів, вчСРП та лептину були достовірно вищими у пацієнтів з ІР, тоді як рівень адипонектину був нижчим. Це підтверджується результатами вивчення кореляційних зв’язків між НОМА-IR, адипокінами, антропометричними та біохімічними параметрами. Таким чином, ретельна оцінка...

6 May 2025 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
OSO.YE. Sklyarova
O.YE. Sklyarova
TMT.A. Maksymets
T.A. Maksymets
OKO.O. Kapustynskyi
O.O. Kapustynskyi
IYI.A. Yuzych
I.A. Yuzych
OKO.S. Kapustynska
O.S. Kapustynska
YSYe.YA. Sklyarov
Ye.YA. Sklyarov
Background. The main cardiovascular risk factors have been investigated over the past few decades. Key factors include dyslipidemia, high blood pressure, smoking, diabetes mellitus and obesity. According to research data, it is important to examine the significance of the homeostasis model of insulin resistance (HOMA-IR) in the Ukrainian population, particularly among individuals with cardio-metabolic risk factors that lead to the development of atherosclerotic, non-atherosclerotic cardiovascular diseases and metabolic complications. Materials and methods. One hundred and ninety-nine individuals were examined: 152 patients with stage I–II arterial hypertension (AH) and 47 individuals without any previously diagnosed diseases. All patients were stratified into six groups according to the number of components of metabolic syndrome (MetS): group 0 — no components of MetS (12 practically healthy individuals); group 1 — the presence of 1 component of MetS; group 2 — the presence of 2 components of MetS; group 3 — three-component MetS; group 4 — four-component MetS; group 5 — five-component MetS. Results. The involvement of a higher number of MetS components was associated with an increase in the IR marker — HOMA-IR. With an increase in the number of MetS components, the body mass index, waist circumference (WC), uric acid and glycemia indicators increased linearly. The incidence of prediabetes, hyperuricemia and AH increased linearly with an increase in the components of MetS. AH and abdominal obesity were early manifestations of metabolic changes. The statistical differences in cardiometabolic risk are more significant when the HOMA-IR exceeded 1.78. When the threshold was exceeded, a significant increase in WC, ttriglycerides, uric acid and C-reactive protein was found in the observed patient groups, and with HOMA-IR values > 3.89, the probability of detecting MetS signs significantly increases. Conclusions. With an increase in the components of MetS, even at the stage of its formation, an increase in the insulin resistance index — HOMA-IR was observed. Abdominal obesity and AH are the most common manifestations at the stage of MetS formation. The average HOMA-IR value of 3.89 aligns with the criteria of MetS, while HOMA-IR above 1.78 is associated with a significance of cardio-metabolic risk factors such as WC, triglycerides, uric acid and C-reactive protein.

27 May 2026
Verified
Journal Article
Open access
OBOlga Bondarenko
Olga Bondarenko
TMTetiana Maksymets
Tetiana Maksymets
Vladyslav BardashVladyslav Bardash
Vladyslav Bardash
The objective: to evaluate the clinical efficacy and tolerability of Gastritol® oral drops in patients with functional dyspepsia (FD). Materials and methods. A multicenter, open-label, controlled study was conducted involving 533 patients aged 18–45 years with diagnosed FD. The study group (SG) – 288 patients – received standard therapy (a proton pump inhibitor (PPI) and a prokinetic/antispasmodic) combined with Gastritol® (20–30 drops 3 times daily). The control group (CG) – 245 patients – received the standard regimen only. Evaluation was performed using the Gastrointestinal Symptom Score (GIS), a physician-rated scale, and quality of life parameters on the 1st and 21st days of treatment. Statistical analysis was performed using R environment (version 4.5.1). Results. The addition of Gastritol® provided a statistically significant advantage in symptom relief compared to standard therapy (PPIs + prokinetic/antispasmodic), p < 0.001. The most pronounced dynamics in the SG were observed regarding epigastric pain, feeling of fullness, bloating, and early satiety. The clinical success rate (4–5 points on the physician-rated scale) in the Gastritol® group was 83.7% vs 52.2% in CG (p < 0.0001). The chances of successful treatment increased 4.69-fold (Odds Ratio = 4.69; 95% Confidence Interval [3.14; 7.00]), with a number needed to treat (NNT) of 3.2. Combined therapy was associated with a significantly higher level of compliance (96.5% vs 86.9%) and substantial improvement in patients’ psychoemotional and physical well-being (p < 0.0001). Conclusions. Inclusion of Gastritol® in standard treatment protocols for FD allows for more profound and rapid relief of dyspeptic syndrome. The drug demonstrates a favorable safety profile and high clinical significance, ensuring recovery for every third additional patient. The multi-target action of the herbal extracts contributes to effective restoration of quality of life and increased treatment adherence.

31 March 2024 in Ukrainian Therapeutical Journal
Verified
Journal Article
Open access
PDF file
TMT. A. Maksymets
T. A. Maksymets
AHA. T. Horbey
A. T. Horbey
NKN. V. Karpyshyn
N. V. Karpyshyn
BBB. B. Bodrevych
B. B. Bodrevych
ESE. Y. Sklyarov
E. Y. Sklyarov
ЄСЄ. Я. Скляров
Є. Я. Скляров
Ganoderma is a medicinal mushroom that has been used in traditional Chinese medicine for centuries. It contains a wide range of biologically active therapeutic molecules that have an anti‑inflammatory, immunomodulatory effect and contribute to the normalization of respiratory tract function. Objective — to evaluate the effectiveness of the Asthmagan drug in the complex therapy of chronic obstructive pulmonary disease (COPD). Materials and methods. Examinations involved 40 hospitalized patients with a verified diagnosis of COPD, aged 18 to 70 years. In addition to standard examinations, leukotriene B4 (LTB4) was determined. Asthmagan capsules were added to the scheme of complex inpatient and outpatient treatment. Results. On admission, patients complained of breathlessness and cough with wheezing and sputum production. Blood tests showed leukocytosis, elevated ESR, hyperfibrinogenemia, and increased C‑reactive protein levels. According to the results of the correlation analysis, positive correlations were found between pro‑inflammatory markers and negative correlations between LTB4 and external respiration indicators. A tendency to LTB4 reduction was noted. After the treatment, positive dynamics were observed in all patients, and in the group of patients with Asthmagan inclusion, there was a significant improvement in external respiration function and all components of the quality of life according to the St. George’s Respiratory Questionnaire (SGRQ). Tolerability of Asthmagan was positive, side effects were not recorded. Conclusions. During the inpatient treatment of patients with COPD with the inclusion of the drug Asthmagan, regression of complaints and clinical manifestations of COPD, a decrease in the level of pro‑inflammatory markers and a tendency to LTB4 levels reduction were noted. Improvement in the quality of life along with a significant increase in the external respiration indicators testified the increase in the effectiveness of COPD treatment by including Asthmagan in the complex treatment.

15 June 2025 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
Vladyslav BardashVladyslav Bardash
Vladyslav Bardash
TMTetiana Maksymets
Tetiana Maksymets
ESEugen Sklyarov
Eugen Sklyarov
Fibroblast growth factor 23 (FGF23) is a phosphotropic hormone secreted by osteoblasts and osteocytes into the systemic circulation. It exerts its effects on the kidneys, parathyroid glands, heart, and bones. FGF23 is a critical phosphaturic hormone that, alongside parathyroid hormone (PTH), regulates phosphate reabsorption and calcitriol (1,25(OH)₂D) synthesis in the kidneys. The present study aimed to evaluate the diagnostic and prognostic significance of fibroblast growth factor 23 in patients undergoing hemodialysis. Methods. A total of 88 patients were examined in this cross-sectional study. The cohort comprised 36 women (40.9%; 95% CI 30.64–51.18) and 52 men (59.1%; 95% CI 48.82–69.36), with a mean age of 55.81 ± 13.14 years. Group 1 consisted of 69 patients with stage 5 chronic kidney disease (CKD) receiving renal replacement therapy via hemodialysis, while Group 2 included 19 patients with stage 3 CKD. Results. FGF23 levels were elevated in 67 patients (97.1%; 95% CI 91.87–99.72) in Group 1, with a median (Me) of 1258.32 pg/mL (interquartile range [IQR] 169.46–1338.46). In Group 2, FGF23 levels were elevated in 18 patients (94.7%; 95% CI 80.58–100), with a median of 150.5 pg/mL (IQR 74.22–929.12). A significant difference was observed between the groups (p < 0.05). The median duration of hemodialysis in Group 1 was 15 months (IQR 8–36). In Group 1, correlation analysis revealed weak associations between FGF23 and phosphorus (r = 0.13; p > 0.05), total calcium (r = 0.04; p < 0.05), ionized calcium (r = 0.02; p < 0.05), and parathyroid hormone (r = 0.08; p > 0.05). Significant correlations were found between FGF23 and creatinine (r = 0.41; p < 0.005), urea (r = 0.33; p < 0.005), urine volume (r = -0.75; p < 0.005), and hemodialysis duration (r = 0.57; p < 0.005). Regression analysis for predicting residual urine volume based on FGF23, creatinine, urea, and hemodialysis duration yielded an R² of 0.7369, F-statistic of 92.45 (p < 0.0001), standard error of residuals of 5.843, and residual degrees of freedom of 66. Conclusions. The weak correlations between FGF23 and calcium-phosphorus metabolism indicate that FGF23 is not a suitable diagnostic marker for mineral and bone disorders (CKD-MBD) in patients undergoing hemodialysis. However, FGF23 is a significant predictor of residual urine volume in hemodialysis patients, as demonstrated by the regression analysis. The model, incorporating FGF23 and hemodialysis duration, explains 73.7% of the variation in urine volume, highlighting its strong prognostic capability. These findings underscore the clinical significance of FGF23 as a biomarker for assessing residual renal function in dialysis patients.